Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology

Jeremy Bordeaux; Rachel Blitzblau; Sumaira Z. Aasi; Murad Alam; Arya Amini; Kristin Bibee; Diana Bolotin; Pei Ling Chen; Carlo M. Contreras; Dominick DiMaio; Jessica M. Donigan; Jeffrey M. Farma; Karthik Ghosh; Kelly Harms; Nicole LeBoeuf; John Nicholas Lukens; Susan Manber; Lawrence Mark; Theresa Medina; Kishwer S. Nehal; Paul Nghiem; Kelly Olino; Gyorgy Paragh; Soo Park; Tejesh Patel; Jason Rich; Ashok R. Shaha; Bhavina Sharma; Yemi Sokumbi; Divya Srivastava; Valencia Thomas; Courtney Tomblinson; Puja Venkat; Yaohui Gloria Xu; Siegrid Yu; Mehran Yusuf; Beth McCullough; Sara Espinosa

doi:10.6004/jnccn.2025.0001

Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology

Jeremy Bordeaux, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Diana Bolotin, Pei Ling Chen, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Kelly Harms, Nicole LeBoeuf, John Nicholas Lukens, Susan Manber, Lawrence Mark, Theresa Medina, Kishwer S. NehalPaul Nghiem, Kelly Olino, Gyorgy Paragh, Soo Park, Tejesh Patel, Jason Rich, Ashok R. Shaha, Bhavina Sharma, Yemi Sokumbi, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja Venkat, Yaohui Gloria Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, Sara Espinosa

Research output: Contribution to journal › Article › peer-review

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.

Original language	English
Article number	e250001
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	23
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2025.0001
State	Published - Jan 2025

Keywords

Combined Modality Therapy/methods
Dermatofibrosarcoma/therapy
Humans
Medical Oncology/standards
Neoplasm Recurrence, Local/therapy
Skin Neoplasms/therapy

Access to Document

10.6004/jnccn.2025.0001

Cite this

Bordeaux, J., Blitzblau, R., Aasi, S. Z., Alam, M., Amini, A., Bibee, K., Bolotin, D., Chen, P. L., Contreras, C. M., DiMaio, D., Donigan, J. M., Farma, J. M., Ghosh, K., Harms, K., LeBoeuf, N., Lukens, J. N., Manber, S., Mark, L., Medina, T., ... Espinosa, S. (2025). Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. JNCCN Journal of the National Comprehensive Cancer Network, 23(1), Article e250001. https://doi.org/10.6004/jnccn.2025.0001

@article{88f7f4ec6ae54d08862dbb20b43dfdb8,

title = "Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology",

abstract = "Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.",

keywords = "Combined Modality Therapy/methods, Dermatofibrosarcoma/therapy, Humans, Medical Oncology/standards, Neoplasm Recurrence, Local/therapy, Skin Neoplasms/therapy",

author = "Jeremy Bordeaux and Rachel Blitzblau and Aasi, {Sumaira Z.} and Murad Alam and Arya Amini and Kristin Bibee and Diana Bolotin and Chen, {Pei Ling} and Contreras, {Carlo M.} and Dominick DiMaio and Donigan, {Jessica M.} and Farma, {Jeffrey M.} and Karthik Ghosh and Kelly Harms and Nicole LeBoeuf and Lukens, {John Nicholas} and Susan Manber and Lawrence Mark and Theresa Medina and Nehal, {Kishwer S.} and Paul Nghiem and Kelly Olino and Gyorgy Paragh and Soo Park and Tejesh Patel and Jason Rich and Shaha, {Ashok R.} and Bhavina Sharma and Yemi Sokumbi and Divya Srivastava and Valencia Thomas and Courtney Tomblinson and Puja Venkat and Xu, {Yaohui Gloria} and Siegrid Yu and Mehran Yusuf and Beth McCullough and Sara Espinosa",

year = "2025",

month = jan,

doi = "10.6004/jnccn.2025.0001",

language = "English",

volume = "23",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "1",

}

Bordeaux, J, Blitzblau, R, Aasi, SZ, Alam, M, Amini, A, Bibee, K, Bolotin, D, Chen, PL, Contreras, CM, DiMaio, D, Donigan, JM, Farma, JM, Ghosh, K, Harms, K, LeBoeuf, N, Lukens, JN, Manber, S, Mark, L, Medina, T, Nehal, KS, Nghiem, P, Olino, K, Paragh, G, Park, S, Patel, T, Rich, J, Shaha, AR, Sharma, B, Sokumbi, Y, Srivastava, D, Thomas, V, Tomblinson, C, Venkat, P, Xu, YG, Yu, S, Yusuf, M, McCullough, B & Espinosa, S 2025, 'Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 23, no. 1, e250001. https://doi.org/10.6004/jnccn.2025.0001

TY - JOUR

T1 - Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology

AU - Bordeaux, Jeremy

AU - Blitzblau, Rachel

AU - Aasi, Sumaira Z.

AU - Alam, Murad

AU - Amini, Arya

AU - Bibee, Kristin

AU - Bolotin, Diana

AU - Chen, Pei Ling

AU - Contreras, Carlo M.

AU - DiMaio, Dominick

AU - Donigan, Jessica M.

AU - Farma, Jeffrey M.

AU - Ghosh, Karthik

AU - Harms, Kelly

AU - LeBoeuf, Nicole

AU - Lukens, John Nicholas

AU - Manber, Susan

AU - Mark, Lawrence

AU - Medina, Theresa

AU - Nehal, Kishwer S.

AU - Nghiem, Paul

AU - Olino, Kelly

AU - Paragh, Gyorgy

AU - Park, Soo

AU - Patel, Tejesh

AU - Rich, Jason

AU - Shaha, Ashok R.

AU - Sharma, Bhavina

AU - Sokumbi, Yemi

AU - Srivastava, Divya

AU - Thomas, Valencia

AU - Tomblinson, Courtney

AU - Venkat, Puja

AU - Xu, Yaohui Gloria

AU - Yu, Siegrid

AU - Yusuf, Mehran

AU - McCullough, Beth

AU - Espinosa, Sara

PY - 2025/1

Y1 - 2025/1

N2 - Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.

AB - Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.

KW - Combined Modality Therapy/methods

KW - Dermatofibrosarcoma/therapy

KW - Humans

KW - Medical Oncology/standards

KW - Neoplasm Recurrence, Local/therapy

KW - Skin Neoplasms/therapy

UR - http://www.scopus.com/inward/record.url?scp=85215402256&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2025.0001

DO - 10.6004/jnccn.2025.0001

M3 - Article

C2 - 39819674

AN - SCOPUS:85215402256

SN - 1540-1405

VL - 23

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

M1 - e250001

ER -

Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this